HEALTHIA LIMITED (HLA)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLA - HEALTHIA LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.41
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.75

21 Sep
2023

0.000

OPEN

$1.75

0.000

HIGH

$1.75

80,531

LOW

$1.75

TARGET
$2.83 61.7% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
HLA: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx - 2.8 8.9 xxx
DPS (cps) xxx 2.0 4.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 54.0% 100.0% xxx
PE Ratio xxx N/A 19.7 xxx
Dividend Yield xxx N/A 2.5% xxx
Div Pay Ratio(%) xxx N/A 48.3% xxx

Dividend yield today if purchased 3 years ago: 1.92%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.14

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/09 - ex-div 2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx4.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx252.6 M
Book Value Per Share xxxxxxxxxxxxxxx109.8
Net Operating Cash Flow xxxxxxxxxxxxxxx22.6 M
Net Profit Margin xxxxxxxxxxxxxxx2.48 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx4.32 %
Return on Invested Capital xxxxxxxxxxxxxxx2.24 %
Return on Assets xxxxxxxxxxxxxxx1.66 %
Return on Equity xxxxxxxxxxxxxxx4.32 %
Return on Total Capital xxxxxxxxxxxxxxx9.06 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx13.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx21 M
Long Term Debt xxxxxxxxxxxxxxx146 M
Total Debt xxxxxxxxxxxxxxx167 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx6 M
Price To Book Value xxxxxxxxxxxxxxx0.92

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx6.5 M
Capex % of Sales xxxxxxxxxxxxxxx2.59 %
Cost of Goods Sold xxxxxxxxxxxxxxx202 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

15/03/2023

1

Buy

$2.83

61.71%

Shaw and Partners found Healthia's first half revenue and underlying earnings result to be in line with its expectations, and noted the company reiterated full year guidance for earnings above $40m. 

The broker described Healthia's outlook as inspiring confidence. The company is set to test marketing initiatives in the approaching fourth quarter, focused on cross promotion to existing patients which could offer upside revenue risk. 

The Buy rating is retained and the target price increases to $2.83 from $2.78.

FORECAST
Shaw and Partners forecasts a full year FY23 dividend of 4.30 cents and EPS of 8.90 cents.
Shaw and Partners forecasts a full year FY24 dividend of 4.80 cents and EPS of 12.00 cents.
Access Stockbroker Research History >

HLA STOCK CHART

FNArena News on HLA

1
Australian Broker Call *Extra* Edition – Mar 15, 2023

Mar 15 2023 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Mar 02, 2023

Mar 02 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Feb 28, 2023

Feb 28 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Feb 08, 2023

Feb 08 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Feb 06, 2023

Feb 06 2023 - Daily Market Reports

Latest Healthcare services News

1
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
2
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
3
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
4
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
5
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
6
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
7
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
8
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
9
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
10
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia